322 related articles for article (PubMed ID: 21437243)
1. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
[TBL] [Abstract][Full Text] [Related]
2. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
[TBL] [Abstract][Full Text] [Related]
3. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
[TBL] [Abstract][Full Text] [Related]
4. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.
Wu X; Ge H; Lemon B; Vonderfecht S; Weiszmann J; Hecht R; Gupte J; Hager T; Wang Z; Lindberg R; Li Y
J Biol Chem; 2010 Feb; 285(8):5165-70. PubMed ID: 20018895
[TBL] [Abstract][Full Text] [Related]
5. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
[TBL] [Abstract][Full Text] [Related]
6. Making way for suppressing the FGF19/FGFR4 axis in cancer.
Prieto-Dominguez N; Shull AY; Teng Y
Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
[TBL] [Abstract][Full Text] [Related]
7. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
8. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity.
Wang C; Yang C; Chang JY; You P; Li Y; Jin C; Luo Y; Li X; McKeehan WL; Wang F
Curr Mol Med; 2014; 14(6):703-711. PubMed ID: 25056539
[TBL] [Abstract][Full Text] [Related]
10. Fundamentals of FGF19 & FGF21 action in vitro and in vivo.
Adams AC; Coskun T; Rovira AR; Schneider MA; Raches DW; Micanovic R; Bina HA; Dunbar JD; Kharitonenkov A
PLoS One; 2012; 7(5):e38438. PubMed ID: 22675463
[TBL] [Abstract][Full Text] [Related]
11. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract][Full Text] [Related]
12. Liver-specific activities of FGF19 require Klotho beta.
Lin BC; Wang M; Blackmore C; Desnoyers LR
J Biol Chem; 2007 Sep; 282(37):27277-27284. PubMed ID: 17627937
[TBL] [Abstract][Full Text] [Related]
13. Salvianolic acid B blocks hepatic stellate cell activation via FGF19/FGFR4 signaling.
Tian S; Chen M; Wang B; Han Y; Shang H; Chen J
Ann Hepatol; 2021; 20():100259. PubMed ID: 32980439
[TBL] [Abstract][Full Text] [Related]
14. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.
Kurosu H; Choi M; Ogawa Y; Dickson AS; Goetz R; Eliseenkova AV; Mohammadi M; Rosenblatt KP; Kliewer SA; Kuro-O M
J Biol Chem; 2007 Sep; 282(37):26687-26695. PubMed ID: 17623664
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
17. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
18. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.
Wu X; Li Y
Aging (Albany NY); 2009 Dec; 1(12):1023-7. PubMed ID: 20157585
[TBL] [Abstract][Full Text] [Related]
19. The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.
Li Q; Zhao Q; Zhang C; Zhang P; Hu A; Zhang L; Schroder PM; Ma Y; Guo Z; Zhu X; He X
J Physiol Biochem; 2018 May; 74(2):247-260. PubMed ID: 29468415
[TBL] [Abstract][Full Text] [Related]
20. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
